ArticleJournal of clinical epidemiology2026
An agent-based model of the effects of limited vaccination on novel respiratory infections.
Article in Journal of clinical epidemiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectivesVaccination is a safe and effective method for preventing infectious diseases but for novel pathogens vaccine supplies may be limited. We modeled distribution of a limited vaccine supply to specific age groups to investigate the effectiveness at preventing infection and mortality of a novel influenza-like virus.
methodsWe used the agent-based modeling platform Framework for Reconstructing Epidemic Dynamics. Limited supplies of vaccine were administered to target age groups. Increased vaccination rates in the 5-17 year old age group tested the ability of single-age group vaccination to interrupt viral transmission. Mortality was estimated using patterns associated with historic pandemic respiratory pathogens.
resultsIn all cases limited vaccination had relatively little impact on overall infections. Distribution of vaccine to 5-17 years olds stopped transmission only at very high vaccine coverage, high vaccine effectiveness and relatively low viral transmissibility. The best strategy for decreasing mortality in all modeled scenarios was to target the age group with the highest mortality.
conclusionResults suggests that in the event of a highly transmissible disease, limited vaccine supplies will not interrupt transmission. Vaccine distribution protecting the most vulnerable from severe outcomes, even without limiting transmission, was the most effective strategy for preventing mortality. PLAIN LANGUAGE SUMMARY: In the case of an emerging disease, vaccine supplies may be limited during the time of high transmission. In such a situation, vaccinating the age group with the highest transmission rate may not be the best strategy to limit mortality, since it will not stop transmission or produce herd immunity. Vaccination may be better used to target the age group with the highest mortality, which may be different for different diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.